ABSTRACT
BowelScreen paused activity in March 2020 to prioritise the response to the COVID-19 pandemic. The aim of this study was to examine the impact of this delay. Cases affected by the pause and subsequently completed were compared to the same period in 2019. Endoscopy and histology data were obtained from the BowelScreen database and patient records. One-hundred and seven colonoscopies were performed during the study period. This compared with 224 colonoscopies during the same period in 2019. Median lead time to colonoscopy in 2020 was 74 days compared to 34 days in 2019. Adenoma detection rate was 59% for both periods. Advanced adenoma and cancer detection rates were similar in both periods. While there was a marked reduction in activity and significant delays for BowelScreen patients during the first wave of the COVID-19 pandemic, this does not appear to have impacted on clinical outcomes for patients who attended for screening colonoscopy.
Subject(s)
Adenoma , COVID-19 , Colorectal Neoplasms , Humans , SARS-CoV-2 , Pandemics/prevention & control , Early Detection of Cancer , Colorectal Neoplasms/diagnosis , Colorectal Neoplasms/epidemiology , Colonoscopy , Mass Screening , Adenoma/diagnosis , Adenoma/epidemiologyABSTRACT
Policies in relation to paging are designed to achieve effective in-hospital communication. This study recorded data in relation to pages received by interns over a two-week period. A survey was conducted assessing perceptions on paging and existing hospital policy. Four interns collected data in relation to 20 regular-day, 4 extended-day and 4 on-call (two weekday and two weekend) shifts (n = 423 pages). Sixty-nine pages (16%) were made during pager-free periods. On average 3 minutes per hour were spent dealing with pages. Compliance with ISBAR ranged from 50.1% to 83.4%. Of the episodes where pages were made during protected times (n = 85), 67% did not meet urgent criteria. While the majority of these pages were from nurses, they were less likely to violate the policy than other staff (relative risk 0.648, p = 0.016). Efforts need to be made to ensure pager-free periods are respected in the interest of effective communication, staff morale and protected training time.
Subject(s)
Hospital Communication Systems/standards , Internship and Residency , Medical Staff, Hospital , Hospitals/standards , Humans , Ireland , Organizational Policy , Quality of Health CareABSTRACT
BACKGROUND: Neuroepithelial transforming gene 1 (NET1) mediates tumour invasion and metastasis in a number of cancers, including gastric adenocarcinoma. It is an indicator of poor prognosis in breast cancer and glioma. This study examined NET1 expression and its prognostic significance in patients with adenocarcinoma of the oesophagogastric junction (AOG). METHODS: NET1 expression was measured by immunohistochemistry in a tissue microarray, constructed from biobanked tissue collected over a 10-year interval, and linked to a prospectively maintained clinical database. RESULTS: Using the Siewert classification for AOG, type I tumours expressed significantly higher levels of NET1, with lowest expression in type III and intermediate levels in type II (P = 0.001). In patients with AOG type III, NET1-positive patients were more likely to be female (P = 0.043), have advanced stage cancer (P = 0.035), had a higher number of transmural cancers (P = 0.006) and had a significantly higher median number of positive lymph nodes (P = 0.029). In this subgroup, NET1-positive patients had worse median overall (15 versus 23 months; P = 0·025) and disease-free (11 versus 36 per cent; P = 0.025) survival compared with NET1-negative patients. CONCLUSION: Although existing data show differences in clinical and prognostic indices across AOG subtypes, there are no studies showing differences in tumour biology. These data suggest NET1, a known mediator of an aggressive tumour phenotype in a number of gastrointestinal cancers, is expressed differentially across AOG subtypes and may be of prognostic significance in the clinical management of this condition.
Subject(s)
Adenocarcinoma/genetics , Esophageal Neoplasms/genetics , Esophagogastric Junction , Neoplasm Proteins/genetics , Oncogene Proteins/genetics , Adenocarcinoma/mortality , Adult , Aged , Aged, 80 and over , Analysis of Variance , Disease-Free Survival , Esophageal Neoplasms/mortality , Female , Gene Expression , Humans , Kaplan-Meier Estimate , Lymphatic Metastasis , Male , Middle Aged , Prognosis , Prospective StudiesSubject(s)
Crohn Disease/diagnosis , Irritable Bowel Syndrome/diagnosis , Sickness Impact Profile , Female , Humans , MaleABSTRACT
BACKGROUND: While the Crohn's disease activity index (CDAI) is the gold standard for defining clinical endpoints in Crohn's disease (Crohn's) clinical trials, its ability to distinguish symptoms due to inflammation from those that are non-inflammatory has been questioned. AIM: To compare CDAI scores in patients with Crohn's and those with Irritable Bowel Syndrome (IBS). METHODS: This was a prospective, cross-sectional cohort study of 91 patients with either Crohn's (n = 44) or IBS (n = 47). Total CDAI and individual component scores were recorded and comparisons were made between Crohn's and IBS patients. RESULTS: Mean CDAI scores were higher in the IBS patients (183 vs. 157, P = 0.1). Sixty-two per cent (n = 29) of IBS patients had CDAI scores greater than 150. Mean CDAI haematocrit score (35.9 vs. 23.0, P = 0.02) and CRP level (6.8 vs. 2.0, P = 0.002) were higher in the Crohn's group. Analysis of CDAI sub-scores demonstrated that IBS patients had significantly higher pain (mean 1.7 vs. 0.8, P = 0.0007) and well-being scores (mean 1.2 vs. 0.8, P = 0.04) relative to patients with Crohn's. Specifically evaluating patients with CDAI greater than 150 (n = 51), IBS patients had higher pain sub-scores (mean 2.4 vs. 1.4, P = 0.002), whereas patients with Crohn's had higher CRP (mean 8.4 vs. 1.8, P = 0.001). CONCLUSIONS: Our study demonstrates that the CDAI does not discriminate patients with symptoms due to active Crohn's from patients with IBS. Patients with IBS can have CDAI scores in the clinically meaningful range. Objective measures, such as CDAI haematocrit score and CRP, are more specific markers of inflammation.
Subject(s)
Crohn Disease/diagnosis , Irritable Bowel Syndrome/diagnosis , Sickness Impact Profile , Adolescent , Adult , Aged , Biomarkers/metabolism , Cohort Studies , Crohn Disease/metabolism , Diagnosis, Differential , Female , Hematocrit , Humans , Irritable Bowel Syndrome/metabolism , Male , Middle Aged , Prospective Studies , Severity of Illness Index , Young AdultABSTRACT
BACKGROUND: Pneumocystis carinii pneumonia (PCP) is a rare form of pneumonia associated with immune-suppression. It is common in patients with AIDS and with a CD4 count of less than 200 cells/mm(3). We report a case of PCP secondary to immune-suppression in a 41-year-old man with psoriatic arthritis being treated with the immune-modulatory agent etanercept. METHODS: Diagnosis of PCP was made histologically using tissue obtained via transbronchial biopsy. RESULTS: There was a good response to standard treatment with high-dose co-trimoxazole. CONCLUSION: This report highlights a recognised but previously unreported complication of etanercept.
